Peroxidase polymer reagents, 2/13:113
Vector Laboratories has added to its line of Western blot detection reagents two highly active WestVision peroxidase polymer antibody conjugates.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Bio-Rad to acquire MorphoSys’ AbD Serotec, 2/13:113
MorphoSys in December signed a definitive agreement to sell its AbD Serotec research and diagnostic antibody segment to Bio-Rad Laboratories.
Vitamin D test, 2/13:113
Diazyme Laboratories has received FDA 510(k) clearance to market its new 25-hydoxy vitamin D assay, which measures total true 25-hydroxy vitamin D levels in serum and plasma samples. The assay automates the removal of nonspecific protein binding and cross-reactivity that may occur in competing assays, thereby ensuring results will be precise and accurate.
Hemophilia genetics testing, 2/13:113
BloodCenter of Wisconsin’s Diagnostic Laboratories has expanded its genetic testing menu for hemophilia. Its new approach to hemophilia genetics allows BloodCenter to identify the genetic abnormality in greater than 95 percent of all hemophilia patients.
Human monoclonal antibodies for flow cytometry, 2/13:113
Beckman Coulter Life Sciences has added to its flow cytometry portfolio 14 new human monoclonal antibodies from Trillium Diagnostics. The analyte-specific reagents are highly specific, convenient, and flexible. Also offered is a new cell permeabilization reagent.
Trichomonas test, 2/13:113
Hologic has received FDA clearance to market its Aptima Trichomonas vaginalis assay on the company’s automated Panther system.
T. gondii products, 2/13:113
Meridian Life Science offers several new Toxoplasma gondii products.
Chembio: Positive data from syphilis test study, 2/13:112
Chembio Diagnostics reported that data from a study evaluating the sensitivity and specificity of the company’s point-of-care Dual Path Platform (DPP) rapid test for syphilis was recently published online in Clinical Infectious Diseases.
MDxHealth, Ghent form pharmacoepigenomics center, 2/13:112
MDxHealth has joined forces with Ghent University to establish NXTGNT, a pharmacoepigenomics center.
High-volume coagulation analyzer, 2/13:112
Siemens Healthcare Diagnostics Sysmex CS-5100 system, a random-access high-volume coagulation analyzer, is now available in Europe, Africa, Canada, Latin America, Australia, and New Zealand. It is equipped with multi-wavelength preanalytical sample integrity technology, enabling high-volume laboratories to achieve first-run accuracy by identifying and managing unsuitable test specimens before analysis.